Novartis

Novartis
Fabrikstrasse 2, 4056 Basel
Novartis  
Discipline: Medicine/Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Pharmacology - May 16
Overall survival results from MONALEESA-7 with Kisqali (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO -   Primary results of GEOMETRY study for capmatinib (INC280)** in METVAR.ex14-mutated advanced non-small cell lung cancer (NSCLC) at ASCO -   Five-year efficacy and saf
Pharmacology - May 10

Full results from the ASSESS study demonstrate patients with relapsing remitting multiple sclerosis (RRMS) taking Gilenya  (fingolimod) 0.5mg had significantly fewer relapses than patients taking glatiramer acetate 20mg Gilenya showed significant superiority versus glatiramer acetate in ot

Pharmacology - May 9

Xiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline products currently in development -   Xiidra is the first and only prescription treatment app

Pharmacology - May 7

Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial -   Mean age of follow-up since dosing with Zolgensma ( onasemnogene abeparvovec-xioi; AVXS-101) was nearly four years, with some patients nearin

Life Sciences - May 5

Interim data reported for the first time from STRONG in SMA Type 2 showed rapid motor function gains and milestone achievements with intrathecal Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) -   New interim data from STR1VE in SMA Type 1 continued to show prolonged event-free survival, incr

Pharmacology - Apr 30

Novartis leads the way at AAN with 53 abstracts, showcasing its broad portfolio of transformative medicines and innovative solutions for people living with spinal muscular atrophy (SMA), multiple sclerosis (MS) and migraine -   Interim data from multiple ongoing clinical studies of Zolgensma * (o

Pharmacology - May 9

Sandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's recently introduced QCE system is first of a kind for multinational pharmaceutical company Regulatory mil

Pharmacology - May 8

Data from EXPAND - the largest randomized controlled trial in a representative secondary progressive MS (SPMS) population - show Mayzent (siponimod) had a meaningful benefit on cognitive processing speed (CPS) for these patients -   Impairment in cognitive function, one of the most disabling aspe

Health - May 7

Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS) , a stage of the disease leading to continuous functional decline, which is often undiagnosed or diagnosed only retrospectively -   Data presented at AAN show that MSProDiscuss TM , a scientifically

Pharmacology - May 2

After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average -   Separate study showed the majority of episodic migraine patients on Aimovig reported at least a 50% reduction in month

Pharmacology - Apr 30

Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors Per licence agreement, EirGenix, Inc is responsible for development and manufacturing; Sandoz has right to commercialize in all mar




website preview

Link

Medicine and Life Sciences